Aptose Biosciences Inc (APTO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aptose Biosciences Inc (APTO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10040
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company which focuses on diagnostics, therapies and treatment for patients with life-threatening cancers. The company advances in new therapeutics which focuses on cellular targets of cancer research coupled with companion diagnostics to identify patient with cancer. Its small molecule cancer therapeutics pipeline includes products which are designed to provide single agent efficacy and efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The company’s product portfolio comprises of CG’806, is a non-covalent small molecule therapeutic agent. Aptose is headquartered in Toronto, Ontario, Canada.

Aptose Biosciences Inc (APTO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Aptose Biosciences to Raise up to USD20 Million in Financing 11
Partnerships 13
Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13
Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15
Licensing Agreements 17
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17
OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19
Equity Offering 20
Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20
Aptose Biosciences Raises Funds through Public Offering of Shares 21
Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For US$25.3 Million 22
Lorus Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$7.7 Million 24
Lorus Therapeutics Completes Private Placement Of Units For US$0.9 Million 26
Lorus Therapeutics Completes Private Placement Of Units For US$6.6 Million 27
Aptose Biosciences Inc – Key Competitors 29
Aptose Biosciences Inc – Key Employees 30
Aptose Biosciences Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 06, 2018: Aptose reports results for the third quarter ended september 30, 2018 32
Aug 07, 2018: Aptose reports results for the second quarter ended june 30, 2018 35
May 10, 2018: Aptose Reports Results for the First Quarter Ended March 31, 2018 37
Mar 27, 2018: Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2017 39
Nov 14, 2017: Aptose Reports Results for the Third Quarter Ended September 30, 2017 41
Aug 08, 2017: Aptose Reports Results for the Second Quarter Ended June 30, 2017 43
May 11, 2017: Aptose Reports Results for the First Quarter Ended March 31, 2017 45
Mar 28, 2017: Aptose Reports Fourth Quarter and Year End 2016 Results 47
Corporate Communications 51
Aug 15, 2018: Aptose Biosciences appoints Carol Ashe as Board Director 51
Apr 25, 2018: Aptose Names Caroline M. Loewy As Board Director 52
Mar 27, 2017: Aptose Announces Planned Departure of Chief Business Officer 53
Legal and Regulatory 54
Feb 07, 2018: Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus 54
Product Approvals 55
Jun 29, 2018: FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers 55
Clinical Trials 56
Jun 04, 2018: Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253 56
Apr 17, 2018: Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting 57
Mar 15, 2018: Aptose to Present Preclinical Data of APTO-253 at the 2018 AACR Annual Meeting 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aptose Biosciences to Raise up to USD20 Million in Financing 11
Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13
Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17
OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19
Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20
Aptose Biosciences Raises Funds through Public Offering of Shares 21
Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For US$25.3 Million 22
Lorus Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$7.7 Million 24
Lorus Therapeutics Completes Private Placement Of Units For US$0.9 Million 26
Lorus Therapeutics Completes Private Placement Of Units For US$6.6 Million 27
Aptose Biosciences Inc, Key Competitors 29
Aptose Biosciences Inc, Key Employees 30
Aptose Biosciences Inc, Other Locations 31

List of Figures
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aptose Biosciences Inc (APTO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hilton Worldwide Holdings Inc:企業のM&A・事業提携・投資動向
    Hilton Worldwide Holdings Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hilton Worldwide Holdings Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Oswaldo Cruz Foundation-製薬・医療分野:企業M&A・提携分析
    Summary Oswaldo Cruz Foundation (Oswaldo Cruz) is a provider of research development, vaccines production, drugs, reagents and diagnostic kits. The foundation provides research in experimental models of disease, infectious agent vector biology, information and communication in health, management of …
  • Banco Santander-Chile:企業の戦略・SWOT・財務情報
    Banco Santander-Chile - Strategy, SWOT and Corporate Finance Report Summary Banco Santander-Chile - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • PanAust Ltd:企業の戦略・SWOT・財務分析
    PanAust Ltd - Strategy, SWOT and Corporate Finance Report Summary PanAust Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Bharat Heavy Electricals Ltd (BHEL):電力:M&Aディール及び事業提携情報
    Summary Bharat Heavy Electricals Limited (BHEL) is an integrated power plant equipment manufacturer that designs, manufactures, constructs, tests, commissions and services a broad range of products. Its product portfolio includes transformers, valves and oil field equipment, electrostatic precipitat …
  • International Coffee & Tea, LLC:企業の戦略・SWOT・財務情報
    International Coffee & Tea, LLC - Strategy, SWOT and Corporate Finance Report Summary International Coffee & Tea, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Tragara Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tragara Pharmaceuticals Inc (Tragara Pharmaceuticals) is a pharmaceutical company focused on the clinical and commercial development of its proprietary medicines for the treatment of various cancers. Its lead product candidate TG02, an oral multi-kinase inhibitor facilitates anti-tumor activ …
  • HSS Engineers Berhad (HSSEB):企業の財務・戦略的SWOT分析
    HSS Engineers Berhad (HSSEB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • 3i Infotech Ltd (3IINFOTECH):企業の財務・戦略的SWOT分析
    3i Infotech Ltd (3IINFOTECH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • CAS Medical Systems Inc (CASM):企業の財務・戦略的SWOT分析
    Summary CAS Medical Systems Inc (CASMED) is a medical device company that designs, manufactures and markets technologies and monitors. The company offers technologies and monitors that deliver patient data. Its products comprise FORE-SIGHT absolute tissue oximeter, blood pressure measurement technol …
  • San Juan Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    San Juan Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary San Juan Basin Royalty Trust (SJT) is a trust that has overriding royalty interest divided out of Southland Royalty's oil and gas leasehold and royalty interest in the San Juan Basin of …
  • PDL BioPharma Inc (PDLI):企業の財務・戦略的SWOT分析
    PDL BioPharma Inc (PDLI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • HeidelbergCement AG:戦略・SWOT・企業財務分析
    HeidelbergCement AG - Strategy, SWOT and Corporate Finance Report Summary HeidelbergCement AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Micell Technologies Inc:製品パイプライン分析
    Summary Micell Technologies Inc (Micell) is a medical device company that develops drug delivery systems for the treatment of cardiovascular diseases. The company offers product such as MiStent sirolimus eluting absorbable polymer coronary stent system, a drug-eluting stent that is designed to optim …
  • Nationwide Building Society:企業の戦略・SWOT・財務分析
    Nationwide Building Society - Strategy, SWOT and Corporate Finance Report Summary Nationwide Building Society - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • BlueWillow Biologics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary BlueWillow Biologics Inc (BlueWillow), formerly NanoBio Corp is a biopharmaceutical company that develops intranasal and intramuscular vaccines for the prevention and treatment of infectious diseases. The company’s pipeline products include anthrax, H5 influenza, pertussis, RSV, HSV-2, and s …
  • RHÖN-KLINIKUM AG:企業の戦略・SWOT・財務情報
    RHÖN-KLINIKUM AG - Strategy, SWOT and Corporate Finance Report Summary RHÖN-KLINIKUM AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Innsuites Hospitality Trust:企業の戦略・SWOT・財務分析
    Innsuites Hospitality Trust - Strategy, SWOT and Corporate Finance Report Summary Innsuites Hospitality Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • REVA Medical Inc (RVA):製品パイプライン分析
    Summary REVA Medical Inc (REVA) is a medical device company that develops minimally invasive medical devices. The company’s product includes bioresorbable polymers. Its bioresorbable polymers can be applied to a variety of medical applications. REVA’s fantom sirolimus-eluting bioresorbable scaffold …
  • Chariot Oil & Gas Ltd (CHAR):企業の財務・戦略的SWOT分析
    Summary Chariot Oil & Gas Ltd (CHAR) is an oil and gas exploration company that create transformational stakeholder value through the discovery of material accumulations of hydrocarbons. The company provides services such as drilling and extracting services for oil and gas resources. It also offers …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆